UniProtKB/Swiss-Prot O94925 : Variant p.Ser482Cys
Glutaminase kidney isoform, mitochondrial
Gene: GLS
Feedback ?
Variant information
Variant position:
482
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Cysteine (C) at position 482 (S482C, p.Ser482Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CASGID; increased enzyme activity.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
482
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
669
The length of the canonical sequence.
Location on the sequence:
SCGMYDFSGQFAFHVGLPAK
S GVAGGILLVVPNVMGMMCWS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SCGMYDFSGQFAFHVGLPAKS GVAGGILLVVPNVMGMMCWS
Mouse SCGMYDFSGQFAFHVGLPAKS GVAGGILLVVPNVMGMMCWS
Rat SCGMYDFSGQFAFHVGLPAKS GVAGGILLVVPNVMGMMCWS
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
55 – 669
Glutaminase kidney isoform, mitochondrial 68 kDa chain
Chain
73 – 669
Glutaminase kidney isoform, mitochondrial 65 kDa chain
Binding site
466 – 466
Binding site
484 – 484
Alternative sequence
170 – 669
Missing. In isoform 2.
Mutagenesis
466 – 466
Y -> A. Loss of enzyme activity.
Beta strand
480 – 482
Literature citations
GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.
Rumping L.; Tessadori F.; Pouwels P.J.W.; Vringer E.; Wijnen J.P.; Bhogal A.A.; Savelberg S.M.C.; Duran K.J.; Bakkers M.J.G.; Ramos R.J.J.; Schellekens P.A.W.; Kroes H.Y.; Klomp D.W.J.; Black G.C.M.; Taylor R.L.; Bakkers J.P.W.; Prinsen H.C.M.T.; van der Knaap M.S.; Dansen T.B.; Rehmann H.; Zwartkruis F.J.T.; Houwen R.H.J.; van Haaften G.; Verhoeven-Duif N.M.; Jans J.J.M.; van Hasselt P.M.;
Hum. Mol. Genet. 28:96-104(2019)
Cited for: FUNCTION; INVOLVEMENT IN CASGID; VARIANT CASGID CYS-482; CHARACTERIZATION OF VARIANT CASGID CYS-482;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.